Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373229 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by David Rizzieri, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01373229 is a Phase 1 study that has completed, run by David Rizzieri, MD. The registered enrollment target is 21 participants.
The verdict
NCT01373229, a Phase 1 study, has completed, sponsored by David Rizzieri, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
In research studies, lenalidomide (also called Revlimid) has shown some response in chronic lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after several months of taking the study drug. It is thought that by adding the drug plerixafor (also called Mozobil) responses may be improved and/or occur sooner. The main purpose of this study is to determine the dose of plerixafor that is safe to use in combination with lenalidomide. The study will also look at the response rates of the combination of lenalidomide and plerixafor and the effect the study drugs have on CLL cells.
Interventions
- DRUG Lenalidomide + Plerixafor (+ Rituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01373229
The ClinicalTrials.gov registry entry for NCT01373229 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Rizzieri, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide + Plerixafor (+ Rituximab) is the first listed.
NCT01373229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01373229 about?
NCT01373229 is a clinical study titled "Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)". In research studies, lenalidomide (also called Revlimid) has shown some response in chronic lymphocytic leukemia (CLL); however, responses are usually partial responses that occur after several months of taking the study drug. It is thought that by adding the drug plerixafor (also called Mozobil) re...
What is the current status of trial NCT01373229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01373229?
The interventions under investigation include: Lenalidomide + Plerixafor (+ Rituximab) (DRUG).
Who is sponsoring clinical trial NCT01373229?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.